Image source: Shutterstock

Highlights

  • TLX recorded a 56% YoY revenue increase, reaching AUD 783.2 million, with operating profit surging by 423% YoY.
  • TLX's share price soared by nearly 129% in one year.
  • The company expanded international presence through strategic acquisitions including ARTMS and IsoTherapeutics.
  • FDA Priority Review for TLX250-CDx has been secured, paving the way for potential U.S. market entry.

Telix Pharmaceuticals Limited (ASX: TLX) is an ASX-listed biopharmaceutical company that has seen its share price increase nearly 129% over the past year. The company has demonstrated positive financial performance and achieved significant strategic global expansions.

Financial Performance and Investment in Innovation

In the financial year 2024 (FY24), TLX recorded revenue of AUD 783.2 million, reflecting a 56% YoY increase largely driven by sales of Illuccix®. Operating profit in FY24 surged by an astounding 423% YoY to reach AUD 82.1 million, while cash from operating activities climbed 80% YoY to AUD 43.0 million. During the reported period, the company invested AUD 194.6 million in research and development (R&D), underlining its commitment to advancing its therapeutic pipeline. Strategic acquisitions and manufacturing investments further bolstered these results, contributing to a 70% YoY rise in adjusted EBITDA.

Outlook

Looking forward to FY25, TLX forecasts revenue in the range of AUD 1.18 billion to AUD 1.23 billion. The expected revenue boost is attributed to ongoing Illuccix® sales and additional revenue streams from RLS. The company also anticipates a 20-25% increase in R&D expenditure in FY25, reinforcing its dedication to innovative therapies.

Strategic Acquisitions Enhancing Global Footprint

TLX has strategically expanded its global reach through pivotal acquisitions such as ARTMS and IsoTherapeutics. These moves have enhanced its capabilities in radiopharmaceutical production and opens path for commercialisation. The integration of these assets is expected to further optimise the company’s manufacturing and distribution networks, ensuring it meets the rising demand for its precision medicine products.

Regulatory Milestones and Pipeline Advancements

A significant regulatory milestone was achieved with the U.S. FDA’s acceptance of the Biologics License Application (BLA) for TLX250-CDx (Zircaix®), an investigational PET imaging agent for kidney cancer. With Priority Review status and a PDUFA target date set for 27 August 2025, TLX is poised to potentially launch the first non-invasive diagnostic tool for clear cell renal cell carcinoma (ccRCC) in the U.S. market. Share performance of TLX

TLX shares closed 1.18% lower at AUD 27.54 per share on 5 March 2025. Over the past year, TLX’s share price has increased by whopping 129.50% and in the past six months, it has risen by approximately 57.91%.

52-week high of TLX is AUD 31.97, recorded on 26 February 2025 and 52-week low is AUD 11.16, recorded on 13 March 2024.

Support and Resistance Summary

Note 1: Past performance is neither an Indicator nor a guarantee of future performance.

Note 2: The reference date for all price data, and currency, is 05 March 2025. The reference data in this report has been partly sourced from EODHD/Others.

 

Technical Indicators Defined:

Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.

Resistance: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Resistance 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Resistance 2 may act as the crucial resistance level for the stock.